FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20540
vvasiiiigtoii,	D.C.	20048

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* STEPHENSON BRIAN C					- <u>B</u> 1	2. Issuer Name and Ticker or Trading Symbol BridgeBio Pharma, Inc. [BBIO]										eck all app Direct Office	ck all applicable) Director		ng Person(s) to Issue 10% Own Other (spo		
	(First) (Middle) BRIDGEBIO PHARMA, INC. IPLING STREET					3. Date of Earliest Transaction (Month/Day/Year) 05/16/2022										See Remarks					
(Street) PALO A (City)		tate)	94301 (Zip)		-	4. If Amendment, Date of Original Filed (Month/Day/Year)									Lin	e) X Form Form Pers	Form filed by One Reporting Person Form filed by More than One Reporting Person				
1. Title of Security (Instr. 3) 2. Trai			2. Tran Date	saction	rative Securities Acquaction 2A. Deemed Execution Date, if any (Month/Day/Year)		,	3. 4. Secundary		4. Securi	I. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			5. Amo Securi Benefi Owned	ount of ties cially I Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	Amount (A) o		Price	Transa	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)				
Common Stock				05/1	6/202	6/2022				M		26,680		A	(1)	3:	33,035		D		
Common Stock			05/1	6/202	/2022			F		9,228 ⁽²⁾ D		\$6.7	4 3	323,807		D					
		•	Table II -									osed of, onverti				Owned					
1. Title of Derivative Security (Instr. 3)	Conversion Date or Exercise (Month/Day/Year)		Execution if any	Execution Date, if any		4. Fransaction Code (Instr. 3)		n of		6. Date Exercisi Expiration Date (Month/Day/Yea		•	7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)		es Security	8. Price of Derivative Security (Instr. 5)		e es ally g d ion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Da Ex	ate kercisab		Expiration Date	Title		Amount or Number of Shares						
Restricted Stock Units	(1)	05/16/2022			M			1,710		(3)		(3)		nmon	1,710	\$0.00	13,67	78	D		
Restricted Stock Units	(1)	05/16/2022			M			778		(4)		(4)		nmon	778	\$0.00	8,55	9	D		
Restricted													Cerr								

Explanation of Responses:

(1)

- 1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- 2. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 26,680 shares of Common Stock underlying the Reporting Person's RSUs.

24,192

- 3. The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date
- 4. The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.

(5)

5. The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date

Remarks:

Stock Units

Title: Secretary, Treasurer and Chief Financial Officer

05/18/2022 /s/ Brian C. Stephenson

** Signature of Reporting Person

Common Stock

24,192

\$0.00

Date

169,351

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

05/16/2022

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.